Roche appeals Mircera injunction

Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring U.S. sales of the anemia med, claiming that Mircera doesn't infringe on Amgen's patents after all. Saying that a judge in federal court encouraged the appeal, Roche said it "maintains its position that all of Amgen's patents...asserted against Roche are invalid and not infringed."

Apparently, Roche got tired of waiting for Judge William Young to decide whether to let it sell Mircera in the States. You'll recall that, in giving Amgen its injunction against Mircera, Young said he might let the drug onto the market under certain conditions, including price controls and royalty payments. Roche agreed to the conditions, but Amgen balked--and so Young is appointing a special master to help sift through the technical issues.

Then--as now--Amgen simply said it thinks a permanent injunction against Mircera is the only correct answer. We'll see what the various judges decide.

- check out the item at Pharmalot

Related Articles:
Mircera judge seeks expert guidance
Court sends Mircera case to ITC
Roche accepts judge's deal on Mircera
Mircera gets FDA nod, but blocked by patent case
Amgen wins patent fight with Roche

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.